The treatments for diabetes and obesity, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA), are emerging as promising treatment options in CKD and diabetic kidney disease (DKD) [5,6,7,8,9,10,11]. Here, SLC5A2 is linked to diabetic kidney disease.